7 medtech stories we missed this week: Nov. 3, 2017
[Image from unsplash.com]From Hologic’s new product launch to CapsoVision gettting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Hologic launches new MyoSure device Hologic announced in a Nov. 1 press release that it has launched its MyoSure Manual Device in the U.S. The device is designed to help doctors resect and remove intrauterine tissue easily in an office setting if used with the MyoSure hysteroscope. 2. IntraFuse wins FDA clearance for FlexThread fibula pin IntraFuse has received FDA 510(k) clearance for its FlexThread Fibula Pin System, according to a Nov. 1 press release. The system is designed to help improve outcomes for orthopedic extremity procedures. It has a percutaneous fixation of distal fibula fractures like Danis-Weber B type fractures or trans-syndesmotic fractures. 3. Skyline Medical, Helomics ink personalized cancer care deal Skyline Medical and Helomics have announced their collaboration in a Nov. 1 press release to develop new approaches for personalized cancer diagnosis and care using the Helomics D-CHIP. D-CHIP uses an artificial intelligence-powered bioinformatics engine to show insights from cancer patient data to help with disease diagnosis and develop new diagnostics and therapies. 4. Sensus Healthcare wins Mexico nod Sensus Healthcare has been cleared to sell its SRT-100 in Mexico, according to an Oct. 31 press release. The system has been approved to treat non-m...
We report the first case of colloid goiter diagnosed using EUS-B- FNA technique. A 77-year-old man presented with ophthalmic symptoms and an incidental finding of lung nodule on chest x-ray. The computed tomography of thorax revealed a left upper lobe nodule and an oval shaped left paratracheal lesion near left pole of thyroid gland. EUS-B- FNAC was performed which lead to the diagnosis of colloid goiter. PMID: 32447948 [PubMed - in process]
ConclusionsUnlike [18F]FDG, [18F]BODIPY 1 showed prominent accumulation in BAT under both inactive and stimulated status. [18F]BODIPY 1 may serve as a valuable BAT PET agent to possibly assess BAT mitochondria density, thus BAT thermogenic capacity after further evaluation.
ConclusionsHypoxia modulation may play a role in nal-IRI ’s mechanism of action. Nal-IRI demonstrated greater anti-tumor activity in the more aggressive and hypoxic tumor model. Furthermore, hypoxia imaging provided early prediction of treatment response.
AbstractPurposeTo investigate and validate the potential role of a radiomics signature in predicting the side-specific probability of extracapsular extension (ECE) of prostate cancer (PCa).ProceduresThe preoperative magnetic resonance imaging data of 238 prostatic samples from 119 enrolled PCa patients were retrospectively assessed. The samples with were randomized in a two-to-one ratio into training (n = 74) and validation (n = 45) datasets. The radiomics features were derived from T2-weighted images (T2WIs). The optimal radiomics features were identified from the least absolute shrinkage and s...
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
ConclusionThese data establish that [89Zr]anti-CD11b Ab immunoPET targets CD11b+ cells (TAMCs) with high specificity in a mouse model of GBM, demonstrating the potential for non-invasive quantification of tumor-infiltrating CD11b+ immune cells during disease progression and immunotherapy in patients with GBM.
Publication date: Available online 25 May 2020Source: Life SciencesAuthor(s): Serena L'Abbate, Ilaria Russo, Claudia Kusmic
In this study, we identified a naturally occurring pDC subset expressing high levels of OX40 (OX40+ pDC) enriched in the tumor microenvironment (TME) of head and neck squamous cell carcinoma. OX40+ pDCs were distinguished by a distinct immunostimulatory phenotype, cytolytic function, and ability to synergize with conventional DCs (cDCs) in generating potent tumor antigen–specific CD8+ T cell responses. Transcriptomically, we found that they selectively utilized EIF2 signaling and oxidative phosphorylation pathways. Moreover, depletion of pDCs in the murine OX40+ pDC–rich tumor model accelerated tumor growth. Co...
Conclusions: Multiparametric ultrasonography depicts a non-ionizing, directly accessible and cost-effective imaging modality that allows for the extensive characterization of testicular tumors, thereby helping to discriminate between malignant and benign entity of testicular tumors. PMID: 32449437 [PubMed - as supplied by publisher]
Dear colleagues, please advise concerning this patient: 40 yo male, high PS, diagnosed a couple of years ago of colic cancer that was locally treated. Aug 2020: he was diagnosed of left parietal (at the level of the motor strip) solitary brain lesion. octobre 2020: he underwent a complete resection , followed by cavity SRS 18Gy /1 fr April 2020: refractory seizures MRI showed a relapsing left parietal cavity lesion, whose epicenter was next to the trolard vein. he was re-resected quasi... re-irradiation after single fraction cavity SRS? What dose?